Sign in
TerminatedNo phase

Blood Glucose Target Before and During Exercise in Adults With Type 1 Diabetes Using an Artificial Pancreas

Key facts

Who runs it
Institut de Recherches Cliniques de Montreal
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
6 people enrolled
Started
1 Jul 2023
Ended
30 Apr 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Physical activity trial intervention
Record updated
5 March 2026
Why it stopped
The protocol did not work.

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Males and females aged between 18 and 65 years old
  • Clinical diagnosis of type 1 diabetes for 1 year. (Note: The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.)
  • Treatment using DIY-AID system for 3 months
  • Own a smartphone or tablet to use the mobile application: Keenoa, Fitbit App
  • Using Dexcom G6 and willing to share CGM data with the research team
  • Using rapid- (e.g., Aspart, Lispro or Glulisine) or ultra-rapid (e.g., FiAsp) acting insulin analogs
  • HbA1c < 8.5%

Who cannot take part

  • Major complication within the previous 3 months (e.g., severe hypoglycemia requiring assistance, diabetic ketoacidosis, or cardiovascular event)
  • Restriction in PA due to significant diabetes complications (e.g., severe peripheral neuropathy, active proliferative retinopathy, etc.) or other type of limitations (e.g., orthopedic, severe arthritis, etc.). Uncontrolled hypertension (e.g., blood pressure > 150 mmHg systolic or > 95 mmHg diastolic)
  • Ongoing pregnancy or breastfeeding
  • Inability to give consent

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Despite major technological advances in type 1 diabetes (artificial pancreas), the management of hypoglycemia remains a major challenge, especially during and after physical activity. The primary outcome is to determine the temporary blood glucose (BG) target to be set 60 minutes before aerobic exercise in people with type 1 diabetes (PWT1D) using do-it-yourself automated insulin delivery (DIY-AID) systems. Three glycemic thresholds to be applied 60 minutes before physical activity will be tested in 32 people on AID-DIY: 8.3 (current target for commercial AID systems), 8.8, and 9.3 mmol/L. Each participant will perform 3 sessions of moderate aerobic physical activity (ergocycle) at 60% of vo2peak with a different glycemic target each time (random order). Plasma glucose will be measured every 20 minutes before and during physical activity, and blood glucose measured by continuous glucose reading (DEXCOM) for 24 hours post-intervention. Once the best glycemic target is selected, participants could come to the research center for 1 or 2 more voluntary interventions to test the threshold during 1) fasting exercise and 2) late luteal phase of the menstrual cycle.

The 3 groups in the trial

  • Temporary target of 8.3 mmol/LExisting treatment, for comparison

    Current commercial artificial pancreas thresholds. Temporary target set 60 minutes before the intervention.

    Treatment: Physical activity trial intervention

  • Temporary target of 8.8 mmol/LTreatment being tested

    Temporary target set 60 minutes before the intervention

    Treatment: Physical activity trial intervention

  • Temporary target of 9.3 mmol/LTreatment being tested

    Temporary target set 60 minutes before the intervention

    Treatment: Physical activity trial intervention

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluating the Appropriate Blood Glucose Target Before and During Moderate Intensity Aerobic Exercise in Adults With Type 1 Diabetes Using Do-it-yourself Automated Insulin Delivery (AID) Systems (the GUARDIA [GlUcose tARget DIY-AID] Trial)"
Record updated
5 March 2026